Abstract
Bromfenac (Duract®), a drug approved for pain, was expected to be metabolized by the rat to an acyl glucuronide, a metabolite formed with most compounds of similar structure. During the investigation of metabolite profiles in rat bile following administration of 1 mg/kg iv doses of14C-bromfenac, an acid-labile metabolite was found that degraded to form 14C-bromfenac. Isolation and characterization of this metabolite indicated that it is an unusual conjugate, bromfenac N-glucoside.
Footnotes
-
Send reprint requests to: Sandra Kirkman Gonzales, Wyeth-Ayerst Research, CN 8000, Princeton, NJ 08543.
- Abbreviations used are::
- TMS-glucose
- trimethylsilylglucose
- HPLC
- high-performance liquid chromatography
- LC/MS
- liquid chromatography/mass spectrometry
- GC/MS
- gas chromatography/mass spectrometry
- ESI
- electrospray ionization
- CI
- chemical ionization
- CID
- collision-induced dissociation
- 5-ASA
- 5-aminosalicylic acid
- Received August 13, 1997.
- Accepted May 19, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.